Alnylam Claims Tekmira Infringed RNAi Tech Patents

Law360, New York (January 18, 2012, 9:28 PM EST) -- Alnylam Pharmaceuticals Inc. filed suit Tuesday in Massachusetts federal court against Tekmira Pharmaceuticals Corp., alleging Canada-based Tekmira infringed six patents by selling gene-therapy-related molecules to pharmaceutical giant Bristol-Myers Squibb Co.

The suit claims Tekmira went beyond the scope of a licensing agreement when it agreed to provide small interfering RNA, or RNAi, molecules to Bristol-Myers Squibb in exchange for “an upfront fee of $3 million plus additional consideration,” in deals announced in 2010 and 2011, according to the complaint. Those molecules can be used to effectively...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.